Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 6
1961 9
1962 18
1963 27
1964 46
1965 150
1966 273
1967 369
1968 420
1969 432
1970 431
1971 518
1972 532
1973 523
1974 579
1975 555
1976 625
1977 566
1978 493
1979 544
1980 572
1981 513
1982 457
1983 498
1984 615
1985 572
1986 627
1987 629
1988 689
1989 711
1990 767
1991 809
1992 795
1993 857
1994 859
1995 951
1996 913
1997 907
1998 958
1999 930
2000 892
2001 901
2002 888
2003 905
2004 900
2005 911
2006 870
2007 842
2008 901
2009 803
2010 868
2011 821
2012 807
2013 833
2014 815
2015 785
2016 704
2017 688
2018 635
2019 287
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

36,162 results
Results by year
Filters applied: . Clear all
Page 1
FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice.
Pan X, et al. Cell Metab 2018. PMID 29706566 Free article.
Mechanistically, FGF21 acts on adipocytes and renal cells to promote induction of angiotensin-converting enzyme 2 (ACE2), which in turn converts angiotensin II to angiotensin-(1-7), then inhibits hypertension and reverses vascular damage. ...Otherwise, pharmaceutical inhibition of angiotensin-(1-7) attenuates the protective effect of FGF21 on angiotensin II-induced vascular dysfunction, but not on hypertension. ...
Mechanistically, FGF21 acts on adipocytes and renal cells to promote induction of angiotensin-converting enzyme 2 (ACE2), which in tu …
Angiotensin II (Giapreza): A Distinct Mechanism for the Treatment of Vasodilatory Shock.
Khalique SC and Ferguson N. Cardiol Rev 2019 - Review. PMID 30601161
This approval was based (ATHOS) on the results from the Angiotensin II for the Treatment of High Output Shock study. In this randomized, double-blind, placebo-controlled trial, patients in the angiotensin II group achieved higher rates of target mean arterial pressure and had lower catecholamine requirements in the first 3 hours of therapy compared with patients in the placebo group. ...Safety issues including the risk of thromboembolic events, infection, and delirium have made clinicians cautious in adopting angiotensin II into practice. ...
This approval was based (ATHOS) on the results from the Angiotensin II for the Treatment of High Output Shock study. In this r …
Retinal angiotensin II and angiotensin-(1-7) response to hyperglycemia and an intervention with captopril.
Senanayake PD, et al. J Renin Angiotensin Aldosterone Syst 2018. PMID 30126320 Free PMC article.
HYPOTHESIS: Hyperglycemia decreases angiotensin-(1-7), the endogenous counter-regulator of angiotensin II in the retina. MATERIALS AND METHODS: The distribution and levels of retinal angiotensin II (Ang II) and angiotensin-(1-7) (Ang-(1-7)) were evaluated by confocal imaging and quantitative immunohistochemistry during the development of streptozotocin-induced diabetes in rats. ...Treatment of the diabetic animals with the angiotensin-converting enzyme inhibitor (ACEI) captopril showed a reduced intensity of Ang II staining, whereas increased intensity and distribution were evident with Ang-(1-7) staining. ...
HYPOTHESIS: Hyperglycemia decreases angiotensin-(1-7), the endogenous counter-regulator of angiotensin II in the retina …
Angiotensin II in Vasodilatory Shock.
Wakefield BJ, et al. Crit Care Clin 2019 - Review. PMID 30784606
The Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3) trial demonstrated the vasopressor effects and catecholamine-sparing properties of angiotensin II. As a result, the Food and Drug Administration has approved angiotensin II for the treatment of vasodilatory shock. This review details the goals of treatment of vasodilatory shock in addition to the history, current use, and recent research regarding the use of angiotensin II. ...
The Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3) trial demonstrated the vasopressor effects and catecholam …
Angiotensin II in septic shock.
Jadhav AP and Sadaka FG. Am J Emerg Med 2019 - Review. PMID 30935784
Angiotensin II (AT-II) is a product of the renin-angiotensin-aldosterone system. It is a vasopressor agent that has been recently approved by FDA to be used in conjunction with other vasopressors (catecholamines) in refractory shock and to reduce catecholamine requirements. We have reviewed the physiology and current literature on AT-II in refractory septic/vasodilatory shock. Larger trials with longer duration of follow-up are warranted to address the questions which are unanswered by the ATHOS-3 trial, especially pertaining to its effects on lungs, brain, microcirculation, inflammation, and venous thromboembolism risk....
Angiotensin II (AT-II) is a product of the renin-angiotensin-aldosterone system. It is a vasopressor agent that
Angiotensin II Triggers Peripheral Macrophage-to-Sensory Neuron Redox Crosstalk to Elicit Pain.
Shepherd AJ, et al. J Neurosci 2018. PMID 29976627 Free PMC article.
Using behavioral readouts of pain hypersensitivity induced by angiotensin II (Ang II) injection into mouse hindpaws, our study shows that activation of the type 2 Ang II receptor (AT2R) and the cell-damage-sensing ion channel TRPA1 are required for peripheral mechanical pain sensitization induced by Ang II in male and female mice. ...Findings from a recent clinical trial on a type II angiotensin II receptor (AT2R) antagonist showed effective analgesia for neuropathic pain. ...
Using behavioral readouts of pain hypersensitivity induced by angiotensin II (Ang II) injection into mouse hindpaws, ou …
Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog.
Asada H, et al. Nat Struct Mol Biol 2018. PMID 29967536
Angiotensin II (AngII) plays a central role in regulating human blood pressure, which is mainly mediated by interactions between AngII and the G-protein-coupled receptors (GPCRs) AngII type 1 receptor (AT(1)R) and AngII type 2 receptor (AT(2)R). ...The reported results should help with designing ligands for angiotensin receptors and possibly to other peptide GPCRs....
Angiotensin II (AngII) plays a central role in regulating human blood pressure, which is mainly mediated by interactions betwe
Endothelin-1 and angiotensin-II modulate urotensin-II vasoconstriction in rat aorta exposed to mercury.
Ahmed AH and Maulood IM. Bratisl Lek Listy 2018. PMID 30160135
OBJECTIVES: The aim of this study was to evaluate the possible roles of endothelin-1 and angiotensin-II in urotensin-II vasoconstriction and in endothelial dysfunction induced by mercury. ...Urotensin-II, angiotensin-II and endothelin-1 significantly participated in vascular responses to mercury chloride. CONCLUSION: The novel finding was that urotensin-II is potentiated under the condition of endothelial dysfunction. ...
OBJECTIVES: The aim of this study was to evaluate the possible roles of endothelin-1 and angiotensin-II in urotensin-II
Angiotensin II- and Alzheimer-Type Cardiovascular Aging.
Cooper HA, et al. Circ Res 2018. PMID 30355238 Free PMC article.
Enhanced angiotensin II (Ang II) signal transduction has been implicated in premature aging and evidence exists for the prolongation of life through blockade of the Ang II type-1 receptor (AT(1)R). In this Viewpoint article, we will discuss noteworthy similarities between Ang II pathophysiology and Alzheimer’s disease as potential intervention points to promote healthy aging....
Enhanced angiotensin II (Ang II) signal transduction has been implicated in premature aging and evidence exists for the …
36,162 results
Jump to page
Feedback